News Archive

On 5th June 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) announced that they are starting a review of the ‘benefits and risks of avacopan’. (Statement here). Whilst …

Vasculitis International have issued an important update about investigation into Tavneos (avacopan) by the USA regulator the FDA. Patients on this drug should read the update to understand the situation …

Vasculitis UK will be holding a Patient Day, along with our 2026 AGM on Wednesday 23rd September in Cambridge, UK. More details to follow.

The European Medicines Agency (EMA) has started a review of Tavneos® (avacopan), a medicine used to treat ANCA-associated vasculitis, including GPA and MPA. This review is not due to new safety concerns or side …

The UKIVAS (United Kingdom & All Ireland Vasculitis Society) annual Vasculitis Education event was held in November 2025. It’s a two-day event open to those medical professionals with a special …

We ask you to support VUK and join our AGM online. It is important to register so that we can send you the link to join the meeting, the agenda …

The British Society for Rheumatology has published an updated evidence-based clinical guideline on the safe use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) across the full spectrum of autoimmune rheumatic …

The Autumn 2025 Newsletter is now available online. Those registered to receive it by post should receive their copy within the next few days.

A new report from Kidney Research UK has exposed the shocking reality faced by people living with rare kidney diseases in the UK. The independent study, Collectively common: the devastating …